Welcome to our dedicated page for NGM Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on NGM Biopharmaceuticals stock.
NGM Biopharmaceuticals, Inc. (NGM) is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative, life-changing medicines. With a strong focus on cardio-metabolic and liver diseases, NGM Bio leverages its cutting-edge drug discovery platform to generate a pipeline of first-in-class biologic drug candidates, targeting a wide range of disease areas, including cancer.
NGM Bio's approach is deeply rooted in understanding the biology of hormones, cell receptors, and associated ligands. By investigating these biological mechanisms, the company assembles a comprehensive understanding of protein structure-function relationships. This approach, combined with expertise in protein and antibody engineering, allows NGM Bio to create potential first-in-class therapeutics with optimized pharmacologic profiles efficiently.
On the financial front, NGM Bio reported significant progress in 2023. The company continues to advance its clinical-stage solid tumor oncology portfolio with promising results. Additionally, NGM Bio's ALPINE 4 trial for aldafermin, targeting patients with compensated cirrhosis due to NASH, achieved its primary endpoint with positive results. This indicates clinical impact in a challenging patient population and positions aldafermin for potential late-stage development partnerships.
NGM Bio has also made strides in developing NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA® (pembrolizumab). This combination has shown encouraging responses in heavily pretreated patients with advanced disease, including MSS CRC, which is typically unresponsive to anti-PD-1/L1 monotherapy.
In January 2024, NGM Bio announced its strategy to further focus its development efforts on rare conditions with significant unmet needs, such as Primary Sclerosing Cholangitis (PSC) and Hyperemesis Gravidarum (HG). This strategic shift aims to maximize near-term impact and value creation while staying aligned with NGM Bio's mission to deliver transformative medicines for patients.
Moreover, NGM Bio has entered into a definitive Agreement and Plan of Merger with Atlas Neon Parent, Inc., under which all outstanding shares of NGM Bio will be acquired at a price of $1.55 per share in cash. This acquisition is expected to close in the second quarter of 2024, resulting in NGM Bio becoming a privately held company.
Overall, NGM Biopharmaceuticals, Inc. is at the forefront of ushering in new therapeutic options for various diseases, driven by a robust research pipeline and strategic collaborations. For more information, visit NGM Bio's website.
Belharra Therapeutics has launched a next-generation chemoproteomics platform, emerging from stealth with $130 million in funding. This includes $50 million in Series A financing led by Versant Ventures and an $80 million collaboration with Genentech. The platform allows for the identification of small molecule drug candidates across all protein targets, enhancing drug discovery potentials beyond traditional methods. With a focus on oncology and immunology, Belharra aims to develop therapeutics for challenging conditions.
NGM Biopharmaceuticals (NGM) presented new findings on NGM936, a bispecific T cell engager targeting ILT3 in acute myeloid leukemia (AML), at the ASH Annual Meeting. NGM936 showed potent T cell-dependent cytotoxicity against ILT3+ AML cells while minimizing cytokine release. With ILT3 specificity, it promises targeted treatment for monocytic AML, a subtype with poor prognosis, accounting for 25-30% of AML cases. NGM Bio plans to seek a partner for clinical development in hematologic oncology.
NGM Biopharmaceuticals presented preliminary data on NGM707 at the ESMO I-O Annual Congress, showing it was generally well tolerated up to 1800 mg with no maximum tolerated dose reached. The drug demonstrated linear pharmacokinetics at doses ≥200 mg and early anti-tumor activity in a Phase 1 trial involving 34 patients with various solid tumors as of November 23, 2022. Notably, there were partial responses in one patient and stable disease in six others, with some patients experiencing significant tumor size reductions, including a 70% decrease. Ongoing enrollment aims to expand effective treatment.
NGM Biopharmaceuticals (NASDAQ: NGM) announced that preliminary data from its Phase 1a study of NGM707, an ILT2/ILT4 dual antagonist antibody, will be presented at the ESMO I-O Annual Congress on December 8, 2022. The ongoing trial focuses on patients with advanced solid tumors expressing ILT2 and ILT4. NGM707 aims to reprogram suppressive cells in the tumor microenvironment to encourage anti-tumor immunity. The company plans to enroll approximately 220 patients in this study, which is part of its wider oncology portfolio.
NGM Biopharmaceuticals (NGM) announced the acceptance of an abstract for their bispecific T-cell engager program, NGM936, at the ASH Annual Meeting from December 10-13, 2022. The presentation will cover NGM936's potential in treating ILT3-positive acute myeloid leukemia and multiple myeloma. Dr. Fabiana Perna from Indiana University will present research supporting NGM936's efficacy. The company emphasizes its focus on developing transformative therapies and currently has seven clinical programs, with four in advanced phases.
NGM Biopharmaceuticals reported disappointing results from the Phase 2 CATALINA trial of NGM621 for geographic atrophy, failing to meet its primary endpoint. Updated findings from Phase 1 trials of NGM120 for cancer were shared at prestigious conferences. Financially, the company posted a net loss of $47.3 million for Q3 2022, up from a $28.9 million loss in Q3 2021. Revenue from collaborations decreased significantly, and R&D expenses rose to $46.1 million, driven by ongoing clinical trials. NGM Bio holds $300.2 million in cash, projected to fund operations until Q4 2024.
NGM Biopharmaceuticals (NGM) recently shared findings from the post-hoc analyses of its Phase 2 CATALINA trial for NGM621, aimed at treating geographic atrophy (GA) due to age-related macular degeneration (AMD). The trial's primary endpoint was the change in GA lesion area over 52 weeks. Although initial results showed a 6.3% and 6.5% reduction in lesion area for different dosing schedules, these did not reach statistical significance. However, post-hoc evaluations revealed a promising 21.9% and 16.8% reduction in specific patient subgroups, indicating potential for further exploration.
NGM Biopharmaceuticals announced results from its CATALINA Phase 2 trial of NGM621 for geographic atrophy, revealing that the trial did not meet its primary endpoint of statistically significant reduction in GA lesion area over 52 weeks compared to sham treatment. NGM621 exhibited a favorable safety profile, showing no significant increase in choroidal neovascularization (CNV) and no treatment-related serious adverse events. Further analyses are set to be presented at The Retina Society Annual Scientific Meeting in November.
NGM Biopharmaceuticals, Inc. (NGM) will host a conference call on October 17, 2022, at 8:00 a.m. ET to discuss topline efficacy and safety results from the CATALINA Phase 2 trial of NGM621, targeting geographic atrophy due to age-related macular degeneration. The trial's results are crucial for understanding the potential therapeutic impact of NGM621 on this condition. Investors can access the live webcast and slides on the company's website, which will be archived for 30 days. NGM continues to develop seven clinical programs across various therapeutic areas.
NGM Biopharmaceuticals (NGM) announced promising results from its Phase 1b trial of NGM120, an antibody targeting GFRAL, for metastatic pancreatic cancer. The treatment was well tolerated with no dose-limiting toxicities. Among six evaluable patients, there was a 100% disease control rate, and the 12-month survival rate was 83.3%. Notably, three patients achieved partial responses lasting over 32 weeks, with one ongoing at 90 weeks. Further studies, including a Phase 2 trial, are planned to explore NGM120's efficacy in combination with gemcitabine and Nab-paclitaxel.
FAQ
What is the market cap of NGM Biopharmaceuticals (NGM)?
What does NGM Biopharmaceuticals focus on?
What is the ALPINE 4 trial?
What recent strategic shift did NGM Bio announce?
What is the significance of the NGM Bio and Atlas Neon Parent, Inc. merger?
How is NGM Bio leveraging AI and machine learning?
What are some key highlights from NGM Bio’s recent financial report?
What are the main therapeutic areas NGM Bio is targeting?
What are some NGM Bio products currently in development?
What is NGM Bio's approach to drug discovery?
How can investors access more information about NGM Bio?
